Effects of Rivaroxaban on Atherosclerotic Lesions in Mice
Author Information
Author(s): Qianxing Zhou, Bea Florian, Preusch Michael, Wang Hongjie, Isermann Berend, Shahzad Khurrum, Katus Hugo A., Blessing Erwin
Primary Institution: University of Heidelberg
Hypothesis
Rivaroxaban, a direct FXa inhibitor, attenuates plaque progression and promotes stability of advanced atherosclerotic lesions in an in vivo model.
Conclusion
Chronic administration of rivaroxaban does not affect lesion progression but downregulates expression of inflammatory mediators and promotes lesion stability in apolipoprotein E-deficient mice.
Supporting Evidence
- Rivaroxaban increased the thickness of protective fibrous caps in atherosclerotic lesions.
- Treatment with rivaroxaban reduced mRNA expression of inflammatory mediators like IL-6 and TNF-α.
- Chronic administration of rivaroxaban did not significantly alter the progression of atherosclerotic plaques.
Takeaway
This study looked at how a medicine called rivaroxaban affects heart problems in mice. It found that while it doesn't stop the growth of bad stuff in their arteries, it helps make the arteries stronger and less inflamed.
Methodology
Apolipoprotein E-deficient mice were treated with rivaroxaban for 26 weeks, and various plaque characteristics were analyzed.
Limitations
The study did not achieve significant reduction in lesion progression, and the effects observed may not translate directly to humans.
Participant Demographics
Female apolipoprotein E-deficient mice, 26 weeks old.
Statistical Information
P-Value
<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website